As the U.S. stock market faces heightened volatility amid escalating trade tensions and economic uncertainty, major indices like the Dow Jones and Nasdaq have entered correction and bear market territories, respectively. In such turbulent times, identifying stocks that are trading below their intrinsic value can be a strategic approach for investors seeking potential opportunities in undervalued assets.

Top 10 Undervalued Stocks Based On Cash Flows In The United States

Name Current Price Fair Value (Est) Discount (Est) NBT Bancorp (NasdaqGS:NBTB) $39.65 $78.73 49.6% International Paper (NYSE:IP) $49.18 $98.19 49.9% CI&T (NYSE:CINT) $5.68 $11.36 50% Range Resources (NYSE:RRC) $38.07 $75.64 49.7% Five9 (NasdaqGM:FIVN) $25.24 $50.27 49.8% Elastic (NYSE:ESTC) $82.21 $162.43 49.4% RXO (NYSE:RXO) $15.77 $31.23 49.5% ZEEKR Intelligent Technology Holding (NYSE:ZK) $23.70 $46.94 49.5% Sotera Health (NasdaqGS:SHC) $10.73 $21.24 49.5% AeroVironment (NasdaqGS:AVAV) $117.59 $232.32 49.4%

Click here to see the full list of 189 stocks from our Undervalued US Stocks Based On Cash Flows screener.

Here's a peek at a few of the choices from the screener.

Lantheus Holdings

Overview: Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products for heart, cancer, and other diseases globally with a market cap of approximately $6.68 billion.

Operations: The company's revenue is primarily derived from its diagnostic kits and equipment segment, which generated approximately $1.53 billion.

Estimated Discount To Fair Value: 45.9%

Lantheus Holdings is trading at a significant discount to its estimated fair value, with shares priced at US$97.21 against a fair value estimate of US$179.58. Revenue is forecasted to grow faster than the broader U.S. market, and earnings are expected to increase by 15.81% annually, surpassing market averages. Recent financials show revenue growth but a slight decline in net income year-over-year, while strategic moves include share repurchases and acquiring Evergreen Theragnostics for US$250 million to enhance radiopharmaceutical capabilities.

According our earnings growth report, there's an indication that Lantheus Holdings might be ready to expand. Unlock comprehensive insights into our analysis of Lantheus Holdings stock in this financial health report.NasdaqGM:LNTH Discounted Cash Flow as at Apr 2025

Viant Technology

Overview: Viant Technology Inc. is an advertising technology company with a market cap of $860.33 million.

Operations: The company generates revenue through its Internet Information Providers segment, totaling $289.24 million.

Estimated Discount To Fair Value: 37.6%

Story Continues

Viant Technology appears undervalued, trading at US$12.66, below its estimated fair value of US$20.29, and 37.6% under analysts' consensus targets. Recent earnings showed significant growth with Q4 sales rising to US$90.05 million from US$64.41 million year-over-year and net income increasing to US$1.75 million from US$0.626 million, indicating improved profitability despite a volatile share price and low forecasted return on equity in the long term.

Our growth report here indicates Viant Technology may be poised for an improving outlook. Click here to discover the nuances of Viant Technology with our detailed financial health report.NasdaqGS:DSP Discounted Cash Flow as at Apr 2025

Simulations Plus

Overview: Simulations Plus, Inc. specializes in developing software for drug discovery and development that uses artificial intelligence and machine learning to model, simulate, and predict molecular properties globally, with a market cap of approximately $497.69 million.

Operations: The company's revenue is derived from two main segments: Services, which contribute $30.29 million, and Software, which accounts for $44.15 million.

Estimated Discount To Fair Value: 38.6%

Simulations Plus, trading at US$23.82, is undervalued against its estimated fair value of US$38.76. Despite recent declines in net income and profit margins, earnings are projected to grow significantly at 32.1% annually over the next three years, outpacing the broader US market's growth rate. The company's revenue guidance for 2025 suggests a robust increase of up to 33%, reflecting strong potential despite current challenges in profitability and share performance.

In light of our recent growth report, it seems possible that Simulations Plus' financial performance will exceed current levels. Get an in-depth perspective on Simulations Plus' balance sheet by reading our health report here.NasdaqGS:SLP Discounted Cash Flow as at Apr 2025

Seize The Opportunity

Discover the full array of 189 Undervalued US Stocks Based On Cash Flows right here. Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Looking For Alternative Opportunities?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqGM:LNTHNasdaqGS:DSP and NasdaqGS:SLP.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments